GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hetzer Medical Indonesia Tbk PT MEDS.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

58

+1.75%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in IDR, from our data supplier.

FY2025

Revenue

IDR 6.63bn

FY2019FY2025

Net income

−IDR 8.35bn

FY2019FY2025

Free cash flow

−IDR 2.73bn

FY2019FY2025

Shareholders' equity

IDR 48.30bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueIDR 6.63bnIDR 6.39bnIDR 22.72bnIDR 37.74bnIDR 75.79bnIDR 87.79bnIDR 12.02bn
Gross profit−IDR 1.40bn−IDR 1.39bnIDR 8.39bnIDR 18.53bnIDR 53.60bnIDR 59.17bnIDR 3.03bn
Research and development—————IDR 728.2mIDR 55.5m
Operating income−IDR 8.24bn−IDR 8.57bn−IDR 2.50bnIDR 4.59bnIDR 34.09bnIDR 48.65bnIDR 421.4m
Net income−IDR 8.35bn−IDR 8.53bn−IDR 3.57bnIDR 237.1mIDR 26.63bnIDR 37.96bnIDR 308.4m
Diluted earnings per share-5.34-5.46-2.290.1521.3124.300.20

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsIDR 61.77bnIDR 65.31bnIDR 77.13bnIDR 80.93bnIDR 49.98bnIDR 30.89bnIDR 7.74bn
Cash and short-term investmentsIDR 779.0mIDR 232.1mIDR 665.6mIDR 5.36bnIDR 1.40bnIDR 13.87bnIDR 540.1m
Total liabilitiesIDR 13.47bnIDR 8.69bnIDR 11.97bnIDR 12.14bnIDR 17.52bnIDR 17.86bnIDR 3.51bn
DebtIDR 8.00bnIDR 5.19bnIDR 7.97bnIDR 10.03bnIDR 11.29bnIDR 2.22bnIDR 27.4m
Shareholders' equityIDR 48.30bnIDR 56.62bnIDR 65.16bnIDR 68.79bnIDR 32.46bnIDR 13.03bnIDR 4.23bn
Shares outstanding1,563m1,563m1,563m1,563m1,250m1,563m1,563m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−IDR 1.48bnIDR 2.23bnIDR 3.15bn−IDR 13.02bnIDR 13.48bnIDR 48.68bn−IDR 2.61bn
Capital spending−IDR 1.26bn−IDR 275.8m−IDR 6.09bn−IDR 17.97bn−IDR 27.01bn−IDR 7.38bn−IDR 863.7m
Free cash flow−IDR 2.73bnIDR 1.95bn−IDR 2.94bn−IDR 30.99bn−IDR 13.52bnIDR 41.31bn−IDR 3.47bn
Dividends paid————−IDR 7.20bn−IDR 29.00bn—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueIDR 6.10bnIDR 4.77bnIDR 1.68bnIDR 1.80bnIDR 1.34bnIDR 1.81bn−IDR 369.4mIDR 1.32bn
Gross profitIDR 2.02bnIDR 1.19bn−IDR 427.7m−IDR 326.1m−IDR 450.0mIDR 182.6m−IDR 2.28bn−IDR 441.5m
Operating incomeIDR 434.9m−IDR 351.2m−IDR 2.75bn−IDR 1.77bn−IDR 2.03bn−IDR 1.69bn−IDR 3.30bn−IDR 1.76bn
Net incomeIDR 218.4mIDR 324.6m−IDR 2.62bn−IDR 1.85bn−IDR 2.09bn−IDR 1.78bn−IDR 3.02bn−IDR 1.82bn
Diluted earnings per share0.140.21-1.68-1.18-1.34-1.14-1.93-1.16
Cash from operationsIDR 513.0m−IDR 2.10bnIDR 1.31bn−IDR 458.0m−IDR 1.53bn−IDR 799.0m−IDR 431.0mIDR 331.0m
Capital spending−IDR 908.0m−IDR 879.0m−IDR 1.10bn−IDR 106.0m−IDR 26.0m−IDR 20.0m−IDR 12.0m−IDR 75.0m
Free cash flow−IDR 395.0m−IDR 2.98bnIDR 213.0m−IDR 564.0m−IDR 1.56bn−IDR 819.0m−IDR 443.0mIDR 256.0m
Total assetsIDR 65.42bnIDR 63.79bnIDR 61.77bnIDR 62.63bnIDR 63.87bnIDR 64.62bnIDR 65.31bnIDR 67.97bn
Cash and short-term investmentsIDR 252.7mIDR 177.5mIDR 779.0mIDR 586.6mIDR 712.4mIDR 243.4mIDR 232.1mIDR 412.8m
DebtIDR 5.50bnIDR 6.25bnIDR 7.29bnIDR 7.13bnIDR 5.89bnIDR 4.55bnIDR 5.19bnIDR 5.83bn
Shareholders' equityIDR 48.62bnIDR 48.62bnIDR 48.30bnIDR 50.90bnIDR 52.75bnIDR 54.83bnIDR 56.62bnIDR 59.63bn

Financial ratios

Data as of 8 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin-21.1%-21.8%36.9%49.1%70.7%67.4%—
Operating margin-124.3%-121.9%-11.5%12.1%45.3%55.5%—
Net margin-125.9%-133.5%-15.7%0.6%35.1%43.2%—
Return on equity-17.3%-15.1%-5.5%0.3%82.0%291.4%—
Return on assets-13.5%-13.1%-4.6%0.3%53.3%122.9%—
Free cash flow yield-0.1%1.6%5.7%3.1%31.4%——
Revenue growth3.7%-71.9%-39.8%-50.2%-13.7%630.3%—
Earnings growth-2.2%139.0%-1606.1%-99.1%-29.8%12208.9%—
Current ratio1.17x2.88x3.72x9.03x1.91x1.22x—
Debt to equity0.15x0.05x0.04x0.15x0.35x0.17x—
Equity ratio78.2%86.7%84.5%85.0%65.0%42.2%—
Interest coverage-12.25x-16.15x-3.92x6.00x190.16x4821.94x—
R&D as a share of sales—————0.8%0.5%
Buybacks as a share of market value0.0%0.0%0.0%-25.0%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-44.0%-40.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-21.5%32.8%57.7%—
Operating margin-129.2%-20.0%28.7%—
Net margin-129.6%-27.5%18.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-13.3-9.2-29.8—
Price to sales16.712.24.75.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.